Welcome to the detailed analysis for ascletis.com. This domain is officially recognized as Ascletis Pharma Inc.. According to their official web presence, their primary focus is: "歌礼生物科技(杭州)有限公司".
"歌礼制药有限公司是一家全价值链整合型生物技术公司,聚焦有望成为治疗代谢疾病同类最佳(best-in-class)和同类首创(first-in-class)药物的开发和商业化。利用公司专有的基于结构的AI辅助药物发现(Artificial Intelligence-assisted Structure-Based Drug Discovery,AISBDD)、超长效药物开发平台(Ultra-Long-Acting Platform,ULAP)技术以及口服多肽递送增强技术(Peptide Oral Transport ENhancement Technology,POTENT),歌礼已自主研发多款小分子和多肽候选药物,包括其核心项目ASC30,一款每日一次口服小分子GLP-1R激动剂,用于长期体重管理和糖尿病治疗;ASC30_48FDC,一款每日一次口服小分子双靶点激动剂,为ASC30(GLP-1R激动剂)与ASC48(GIPR激动剂)的固定剂量复方制剂;ASC30_48_39FDC,一款每日一次口服小分子三靶点激动剂,为ASC30(GLP-1R激动剂)、ASC48(GIPR激动剂)与ASC39(胰淀素选择性受体激动剂(SARA))的固定剂量复方制剂;ASC39,一款与eloralintide类似、强效且对胰淀素具有选择性的每日一次口服小分子胰淀素受体激动剂(SARA);ASC30_39FDC,一款每日一次口服小分子双靶点激动剂,为ASC30(GLP-1R激动剂)与ASC39(胰淀素选择性受体激动剂(SARA))的固定剂量复方制剂;ASC36,一款胰淀素多肽,设计为每月一次至每季度一次皮下注射以及每日一次口服;ASC35,一款每月一次皮下注射GLP-1R/GIPR双靶点激动剂多肽;ASC36_35FDC,一款每月一次皮下注射三靶点多肽激动剂,为ASC36(胰淀素受体激动剂)与ASC35(GLP-1R/GIPR激动剂)的固定剂量复方制剂;ASC37,一款GLP-1R/GIPR/GCGR三靶点激动剂多肽,设计为每月一次皮下注射及每日一次口服;以及ASC36_37FDC,一款每月一次皮下注射四靶点激动剂多肽,为ASC36(胰淀素受体激动剂)与ASC37(GLP-1R/GIPR/GCGR激动剂)的固定剂量复方制剂,用于长期体重管理。歌礼已在香港联交所上市(1672.HK)。"
"歌礼宣布同类首创和同类最佳的口服小分子IL-17A抑制剂ASC50治疗斑块状银屑病在美国的28天概念验证临床研究取得积极结果"
"© 2018 Ascletis Pharma Inc. All Rights Reserved 浙公网安备 33010802003344号 浙ICP备11050387号-1 Cookie 设置"
By comparing ascletis.com to other leading websites in its niche, marketers and researchers can identify key traffic sources and growth opportunities. Explore our related resources below to find websites similar to ascletis.com.
Yes, according to our latest analysis, we detected a valid SSL certificate ensuring a secure connection.
As of October 12, 2026, ascletis.com holds an estimated domain authority score of 81/100 based on our VisitRank tracking algorithms.
You can find the best alternatives and similar sites to ascletis.com in our explore section, which includes competitors in the News & Media sector.
Common Misspellings & Typo Domains for ascletis.com: